This document provides a summary of the key topics that will be covered in a market research report on the impacts of macro upheavals in China on the global life sciences industry. The report will examine 10 major upheavals in China, including increased investment from European pharmaceutical companies in China, developments in China's vaccine industry, reforms to regulations and standards, growth of China's clinical research organization industry, exports of medical devices from China, and China's efforts to internationalize its pharmaceutical industry. The report will be useful for companies in the pharmaceutical, medical device, healthcare, and digital health industries.

1. 10 Ways in which
Current Macro
Upheavals in China
will Impact Global
Life Sciences
Industry
A Market Research Report on

2. 2
Unabated European
pharma investment in
China
The highlights and
lowlights faced by Chinese
vaccine developers
Strengthening global
health through
R&D
Accelerating Industrial
Transformation and
Talent Development
Increasing commitments
to health assistance and
cooperation
Focusing on
regulatory reforms
Consolidation within the
service provider
space
Integrating countries
through commercial
partnerships
Export and Sales of Medical
Devices and Consumables
across Nations Globally
Promoting the
Internationalization of the
Pharmaceutical Industry
What would this Report Cover?
10 Macro Upheavals in China Impacting Global Healthcare

3. 3
▪ Big Pharma players are investing in China-specific projects and
growing their footprint across the mainland as China represents an
ever-increasing share of their global profits
▪ In order to more effectively and comprehensively connect with
Chinese medication developers, Boehringer Ingelheim (BI) built a
new hub in Shanghai to consolidate its R&D, and business
development operations in China
▪ Additionally, Novo Nordisk unveiled ambitious intentions to
combine their Chinese and international businesses with an
emphasis on clinical development
▪ Novo Nordisk’s "China Essentials" program seeks to simultaneously
submit clinical trial applications for new drugs in China and
other countries for the first time, with a goal of 90 percent by 2025
▪ An intriguing microcosm of the status of development of the entire
business can be seen in the highs and lows encountered by
Chinese vaccine developers in their quest to deploy a COVID-19
vaccine
▪ While Chinese companies were among the first in the world to
introduce vaccine candidates into the clinic, validating the
advancements made by the country's overall biopharmaceutical
industry and significantly raising the stature of Chinese scientific
research abroad, it was ultimately a Big Pharma-backed vaccine
from Pfizer and German biopharma player BioNTech that first
crossed the finish line
▪ Chinese-developed COVID-19 vaccines received approval for
routine or emergency use in China and several other nations,
including the UAE, Egypt, and Brazil, but not by the US or the EU,
which were regarded as the world's two most stringent regulatory
bodies
Macro Upheavals Impacting Global Healthcare (1/5)
The Highlights and
Lowlights Faced by
Chinese Vaccine
Developers
Unabated European
Pharma Investment in
China

4. 4
Macro Upheavals Impacting Global Healthcare (2/5)
▪ China’s 14th Five-Year Plan calls for an average annual increase
in R&D spending across the industry of more than 10%; in
addition to the requirements for the innovative development of the
pharmaceutical industry in the fundamental principles, these
requirements are also reflected in terms of development goals
▪ By 2025, the share of newly sold innovative items in the increase
in operating revenue for the entire industry will further rise
▪ The National Natural Science Foundation of China (NSFC) and the
China Grand Challenges project were established to promote
scientific and technical innovation that may address important
issues facing emerging nations
▪ The initiative has supported research on AIDS vaccine
development, child and maternal mortality, tuberculosis (TB)
treatments, vaccines, and more at prestigious universities, research
centers, and hospitals in China
▪ Chinese and British agencies convene as part of a bilateral Global
Health Dialogue that determines areas of shared interest for
potential future cooperation
▪ Chinese government is assisting the Africa Centres for Disease
Control and Prevention (CDC) and has also inked MOUs with
the WHO and numerous bilateral partners to address some
healthcare constraints
▪ Private health sector businesses, organizations engaged in health
research, and other entities are being engaged by China and
foreign partners
▪ This might entail setting up a platform for cooperation in global
health and technical professionals and should develop a mutual
understanding as a foundation for more productive collaboration
Integrating Countries
through Commercial
Partnerships
Strengthening Global
Health through R&D

5. 5
Macro Upheavals Impacting Global Healthcare (3/5)
▪ China is collaborating with international partners to remove
obstacles that prevent more high-quality and reasonably priced
Chinese healthcare products from entering the global market, which
could have a larger impact on world health
▪ To provide technical support and support reforms that bring
Chinese regulations and standards in clinical trials, drug approval,
and manufacturing into line with international norms, WHO and the
National Medical Products Administration which is China's main
regulatory agency for drugs and medical devices have come
together
▪ Chinese businesses can more easily pursue concurrent domestic
certification and WHO prequalification of their products
▪ China is promoting global health by covering the agreements for
working with African nations, like FOCAC for health cooperation
▪ Under FOCAC, a forum for China-Africa health development has
been established, and agreements have been made to offer health
aid to African nations
▪ As part of efforts to boost international cooperation, the
Chinese government has signed MOUs with several multilateral
organizations, most notably the WHO for global health
▪ China is actively developing better health policies, demonstrating
its commitment to playing a greater role in global health, and
beginning to demonstrate the thematic goals, kinds of cooperation,
and levels of engagement that the government envisions
Increasing Commitments
to Health Assistance and
Cooperation
Focusing on Regulatory
Reforms

6. 6
Macro Upheavals Impacting Global Healthcare (4/5)
▪ The development of the pharmaceutical industry in China depends
on encouraging technical collaboration in the pharmaceutical
area between business, academia, research facilities, and
hospitals, as well as on maximizing the potential of those working in
that sector globally
▪ In order to improve collaboration with scientific research
institutions and jointly create a national strategic scientific force in
the field of biomedicine, the 14th Five-Year Plan emphasizes its
support for innovative pharmaceutical firms
▪ Additionally, the strategy calls for funding the establishment of
independent pharmaceutical R&D organizations, assisting in the
creation of premier clinical research facilities, and enhancing the
capabilities of clinical research design and research services
▪ The biopharma boom in China has also energized the CRO and
CDMO space, with demand greatly outstripping supply across many
fundamental services, through acquisitions, Chinese pharmaceutical
businesses are expanding their market share and entering the
global pharmaceutical outsourcing sector
▪ In order to increase its CDMO capability and market reach in
Europe, WuXi AppTec made an agreement with Bristol Myers
Squibb to purchase the latter's production plant in Couvet,
Switzerland in 2021
▪ To improve its CMC capabilities in the UK and China, Pharmaron
purchased a commercial API production plant from Recipharm in
the beginning of 2022
▪ These transactions represent a grown Chinese CRO and CMO
market, which grew at a CAGR of 30.8% from 2016 to 2021, much
faster than the global average of 9.5%.
Consolidation within the
Service Provider
Space
Accelerating Industrial
Transformation and
Talent Development

7. 7
Macro Upheavals Impacting Global Healthcare (5/5)
▪ In numerous healthcare sub-sectors, China is the second-largest
healthcare market in the world, offers the potential to global
exporters
▪ The most active and vitally essential segment of the Chinese
healthcare market for international enterprises continues to be
medical equipment
▪ Medical equipment with advanced technology is typically imported,
while low to mid-range market segments are dominated by native
products
▪ China's medical device industry is anticipated to grow at a CAGR of
6.2% from 2020 to 2025, bringing about USD38.4 billion by 2025
▪ The diagnostics, imaging, and consumables subsectors of the
Chinese medical device industry accounted for about 50% of the
market's value
▪ In terms of going worldwide, China is promoting to support
businesses in synchronizing the registration of novel
medications in China and abroad as well as conducting
international multi-center clinical research for developed nations
▪ The globalization of China's pharmaceutical business includes the
process of internationalization that also involves the exit of native
pharmaceutical firms and the admission of foreign
pharmaceutical firms
▪ This is carried out by actively enticing multinational
corporations to establish R&D centers and innovative drug
manufacturing bases in China, as well as by using cooperative
development and technology licensing to realize the entry of foreign
pharmaceutical companies, in order to drive the development of the
domestic pharmaceutical industry companies
Promoting the
Internationalization of the
Pharmaceutical Industry
Export and Sales of
Medical Devices and
Consumables across
Nations Globally

8. Who should buy this report?
MedTech
Players
HealthTech
Companies
Healthcare
Providers
Digital Health
Entities
Pharmaceutical
Players

9. Cost of this report:
$2,500
Annual Subscription:
$125,000 $60,000
(Includes a total of 50 reports)
www.insights10.com
10 Ways in which Technology is Driving Better Efficiency in
Clinical Trials
Digital Therapeutics Regulatory Process, Updates and Trends
Will the Expiry of Humira Market Exclusivity and Entry of its
Biosimilars Move the Needle in BioPharma Market?
From the Fringes to the Forefront: mRNA is here to Transform
Global Health
Melting the Iron Triangle: 10 Healthcare Players aiming
Beyond Health Equality to Conquer Health Equity
Robotics: Embarking a New Era in Surgical Innovations
Topics of Upcoming Reports
Metaverse: Paving the way for Health 4.0
Healthcare Future Outlook 2023
Patient Engagement- a New Standpoint on Care that is
Patient-Centered
E-Rx, the Digital Version of Prescription Improvising the
Chances of Better Patient Outcomes

10. Methodology & Scope

11. 11 A Sample Report on Singapore Physiotherapy Market Analysis I Confidential
Research Methodology
▪ Insights 10’s research methodology delves deeper into the market, covering the macro and micro aspects of the industry. We identify the
key growth drivers, opportunities, and restraints that might promote or hinder the future industry growth along with an expansive
overview of the competitive landscape to help our clients make informed strategic decisions
▪ We implement a mix of primary and secondary research for our market estimate and forecast. The secondary research forms the initial
phase of our study where we conduct extensive data mining, referring to verified data sources such as independent studies, government
and regulatory published material, technical journals, trade magazines, and paid data sources
▪ For forecasting, the following parameters are considered:
❑ Market drivers and restraints along with their current and expected impacts
❑ Technological scenario and expected developments
❑ End use industry trends and dynamics
❑ Trends in the consumer behavior
❑ Regulatory scenario and expected developments
❑ Current capacity and expected capacity additions up to 2030
▪ We assign weights to these parameters and quantify their market impacts using the weighted average analysis to derive the expected
market growth rate
▪ We appoint data triangulation strategies to explore different areas of the market. Our qualitative and quantitative assessments are time-
sensitive, reflecting the most recent value and volume of the market across regions
▪ All our estimates and forecasts are verified through exhaustive primary research with the Key Industry Participants (KIPs)
▪ Currency used in the report is the US dollar (USD), with the market size indicated in USD million/billion (Mn/Bn)

12. 12 A Sample Report on Singapore Physiotherapy Market Analysis I Confidential
Analysis Methodology
Our Analysis Methodology involves three critical stages:
Primary
Research
Secondary
Research
Market Trends
Market Sizing &
Analysis
Data Triangulation &
Validation
Analysis &
Interpretation
Insights
Presentation &
Reporting
Data Collection
Market Data Analysis
& Statistical Model
Interpretation &
Presentation

13. 13 A Sample Report on Singapore Physiotherapy Market Analysis I Confidential
Data Triangulation & Data Validation
Bottom Up Approach
Summarization of revenue
generated from companies
to arrive at total market size
Revenue generated by products &
services offered by companies
Validation from
Primary Interview
Final
Market
Size
Top Down Approach
Final Market size break up to
rest of segmentation
Arriving at market size
of each segment
Validation from
Primary Interview
Final
Summary

14. 14 A Sample Report on Singapore Physiotherapy Market Analysis I Confidential
Key Benefits for Stakeholders from this Report
Study provides an in-depth analysis of the market with current trends and future estimations to elucidate the imminent
investment pockets
Our tools provides stakeholders with a cohesive understanding of the industry outlook, considering the qualitative and
quantitative industry variables
Comprehensive analysis of factors that drive and restrict the market growth is provided
Comprehensive quantitative analysis of the industry from 2021 to 2030F is provided to enable the stakeholders to capitalize on
the prevailing market opportunities
Extensive analysis of the key segments of the industry helps understand the applications and technologies used globally
Our rigorous data collection, thorough statistical analysis and specialist assessments ensure that our clientele has a greater
understanding of the industry space, supply chain, price fluctuations, competitive landscape, and other vital factors

15. 2021
2022-
2030
Report Attribute
Quantitative Units
Report Coverage
Customized Report
Pricing and purchase
options
Revenue in USD Million/Billion (Mn/Bn)
Market Overview, Revenue Forecast, Market
Segmentation, Growth Factors and Trends,
Company Profiles, Competitive Landscape,
Regulatory Landscape, Future Opportunities
Report Customization (5 working days) with
purchase. We will provide you with data that is
currently not a part of our scope as a part of
customization
Avail customized purchase options to meet
your exact research needs
Details
Time Frame
Base Year for
Estimation
Forecast
Period

16. The report is prepared
using a proven
methodology and
insightful research
Reliable
The data is prepared by
a team of highly qualified
& experienced research
analysts & vetted by our
local associates
Expert-verified
Allowing you to
confidently make
smarter business
and strategic
decisions
Real
Covers everything you
would need to know
about the market
including market size,
competitive analysis &
much more
Comprehensive
You do not have to be a
market expert to
understand what really is
happening on the market
and how it works
Easy to read
What kind of Data is Presented
in this Report?
This report presents data, which is:
www.insights10.com

17. About

18. www.insights10.com
A large database of over 30,000 syndicated market
research reports in pharmaceuticals and
healthcare sector at global, regional as well as
country level. We also provide customized
research reports tailor made to suit your needs
Lifesciences Market
Research Reports you
can trust

19. Insights10 is a healthcare focused market
research firm founded with an aim of being an
insights driven company in the data driven world
and delivering actionable insights that can drive
decision and strategy making process for
businesses
Get Insights to take
informed Business
Decisions
www.insights10.com

20. Market Research Reports
across various domains of healthcare
Healthcare
Services
Clinical
Trials
OTC &
Nutraceuticals
Pharmaceuticals
(Diseases & Drugs)
Digital
Health
Medical
Devices

21. Our
Services
1
2
3
4
5
6
10
9
8
7
Market Research Reports
Customized Reports
Primary Research
Database Services
Full-Time Engagement
Conference Coverage
Competitive Intelligence
Strategic Research Projects Regulatory Compliance
Report Subscription Services

22. Our Research Process
01 03
02 04 05
Identification of
Data
Collection of
Data
Market
Dynamics
Collaboration
of Data
Verification &
Analysis
www.insights10.com

23. Statistical Databases
Data
Sources
We have access to multiple highly
reliable free and subscription data
sources. We have many years of
experience to understand which
sources are more dependable for what
and which to prefer for the reliable and
latest information.
Company Websites/Annual Reports
Trade Publications
Online Databases
Published Research Reports
Whitepapers
Press Releases of Key Market Players
www.insights10.com

24. Research Projects Done
Over the years, we have developed an in-depth experience of executing
market analysis at global, regional & country specific level in life sciences.
Our team has
conducted market
research across 62+
global markets in
America, Europe,
Middle East, Africa and
Asia Pacific regions

25. Mukesh is an engineering graduate
with an MBA in Marketing. He is a
seasoned healthcare market
research & marketing professional
with a progressive experience of over
20 years in Life Sciences, Pharma
and Medical Device sectors. With an
in-depth understanding of primary
research, he has conducted
hundreds of interviews of various
stakeholders in pharma & healthcare
& completed several research
projects across life sciences industry.
Ritu has over 6 years of experience in
strategy building, market assessments,
market sizing, and RWE for global MNC
healthcare & biopharma clients across
diff. markets (America, Europe, Africa,
APAC and Middle East). Her areas of
expertise include: Indentifying emerging
trends in life sciences industry,
Competitor landscape assessment,
Disease opportunity assessments etc.
She is a pro in secondary and primary
research with a deep domain expertise
in healthcare sector.
Purav is a physician and an
entrepreneur with 12+ years of
experience in Healthcare & Life
Sciences industry spanning across
strategy, market access, health
informatics and RWE, digital health,
analytics and data science. Purav
studied medicine from Gujarat
University and also completed his MBA
from IIM-Kozhikode. Purav started his
career with Deloitte working on strategy
consulting engagements and also co-
founded ConvergeHealth by Deloitte.
Atharva is a B.Tech (Biotechnology) and
MBA in Hospital and Health Management
with 2 years of experience working in
consulting and project management in
healthcare and Non-Government
organizations. Conducted
comprehensive research and market
sizing exercise to understand the
business potential for modern digital
trends. Conducted comprehensive
secondary research for the subjects
including the UK Mobility Aids market,
Brazil’s Ophthalmology market, etc.
Dr. Purav Gandhi
Founder & CEO
Mukesh Nayak
Head - Marketing
Ritu Baliya
Engagement Manager
Atharva Bahad
Consultant
Project Leadership Team

26. 7 years of experience working with leading organizations in pharma, MedTech
and healthcare domain. Some of our recent clients are mentioned below
… and many more

27. Web: www.insights10.com
Email: insights@insights10.com
Call: (+91) 931 639 7935
Whatsapp: (+91) 931 639 7935
We would be happy to help.